This inventor holds 53 USPTO granted patents and 70 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Lianyungang, CN (2019)
- Jiangsu, CN (2022)
- North Brunswick, NJ (US) (2022)
- Shanghai, CN (2019 - 2024)
Company Filing History:
46 out of 159 
44 out of 100 
4 out of 8 Years Active: 2019-2026
Areas of Expertise:
Title: Innovations and Contributions of Weikang Tao in Diabetes Treatment
Introduction: Weikang Tao, based in Shanghai, China, is a prolific inventor with an impressive portfolio of 39 patents. His work focuses primarily on the development of pharmaceutical compounds with significant therapeutic potential, particularly in the realm of diabetes treatment.
Latest Patents: Among his latest innovations is the patent for a fused imidazole derivative, which includes methods of preparation and medical applications. This derivative is noted for its role as a GLP-1 receptor agonist, making it a promising therapeutic agent in the preparation of drugs aimed at treating and preventing diabetes. The details of the patent elaborate on the pharmaceutical composition containing this derivative, emphasizing its significance in medical research and application.
Career Highlights: Weikang Tao has made substantial contributions to the pharmaceutical industry, primarily through his work with Shanghai Hengrui Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Company Ltd. His career has been marked by a commitment to advancing medical science through innovative research and development in drug formulation and application.
Collaborations: Throughout his career, Weikang has collaborated with notable professionals in the field, including Feng He and Lianshan Zhang. These collaborations have facilitated advancements in research, leading to impactful innovations that benefit patients with diabetes.
Conclusion: Weikang Tao's extensive contributions to pharmaceutical development, particularly in diabetes treatment, underscore the importance of innovation in the medical field. His patents and collaborative efforts continue to pave the way for future advancements in the treatment and prevention of diabetes, showcasing the vital role of inventors in enhancing healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile